You are here:

tinzaparin sodium (Innohep)

Advice

following a full submission

tinzaparin (Innohep Syringe®) is accepted for use within NHS Scotland.

Indication under review: Patients with solid tumours: Extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.

In patients with cancer and VTE, tinzaparin was associated with rates of VTE recurrence that were not significantly different from those with a vitamin K antagonist (VKA).  In a large study it was not significantly different from a VKA for a composite outcome that included symptomatic deep vein thrombosis (DVT), non-fatal and fatal pulmonary embolism (PE), incidental DVT and PE.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tinzaparin.  This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: tinzaparin sodium (Innohep)
SMC Drug ID: 1061/15
Manufacturer: LEO Pharmaceuticals
Indication: Patients with solid tumours: Extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 July 2015

Back